Department of Nephrology, Affiliated Renhe Hospital of China Three Gorges University, Yichang, Hubei, China
The copper chelator tetrathiomolybdate, which blocks the copper-dependent catalytic activity of LOX, is presently undergoing a phase II study (NCT00195091) involving patients with breast cancer at moderate to high risk of recurrence
AOD 9604 is a synthetic hGH-derived peptide fragment with limited early-phase human trial data and no MHRA or EMA Marketing Authorisation
Research Application This formulation is intended for laboratory-based investigation, where each peptide can be examined within controlled environments to observe pathway-specific activity
Higher risks may occur when patients: self-dose without supervision buy peptides from unregulated websites use incorrect dosing combine multiple peptides improperly skip follow-up monitoring ignore nutrition and hydration Patients sometimes assume peptide therapy is natural and therefore completely risk-free
10.3892/etm.2011.382 22 KirkhamP.BarnesP